Clinical Trial: NCT03161353
Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 2| Lead Sponsor: | MedSIR |
| Information Provided By: | MedSIR |
| Last Update Posted: | 2025-04-23 |
Study Overview
Brief Summary
The study assess the early metabolic effects of neoadjuvant treatment with trastuzumab and pertuzumab (± endocrine therapy) on the primary tumor and axillary lymph nodes and their predictive value for pathologic complete response (pCR) in the breast and axilla.
And also assess 3-year invasive disease-free survival (iDFS) in patients with HER2-positive (HER: human epidermal receptor) breast cancer treated with neoadjuvant trastuzumab and pertuzumab (± endocrine therapy) using a FDG-PET response-adapted strategy.
Official Title
Conditions
Intervention / Treatment
- Drug: Perjeta
- Drug: Herceptin
- Drug: Docetaxel
- Drug: Carboplatin
- Drug: Letrozole
- Drug: Tamoxifen
Other Study ID Numbers
- MedOPP096
- 2016-002676-27
- 2016
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Estimated)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | MedSIR |
| Information Provided By: | MedSIR |
| Last Update Posted: | 2025-04-23 |
Study Overview
Brief Summary
The study assess the early metabolic effects of neoadjuvant treatment with trastuzumab and pertuzumab (± endocrine therapy) on the primary tumor and axillary lymph nodes and their predictive value for pathologic complete response (pCR) in the breast and axilla.
And also assess 3-year invasive disease-free survival (iDFS) in patients with HER2-positive (HER: human epidermal receptor) breast cancer treated with neoadjuvant trastuzumab and pertuzumab (± endocrine therapy) using a FDG-PET response-adapted strategy.
Official Title
Conditions
Intervention / Treatment
- Drug: Perjeta
- Drug: Herceptin
- Drug: Docetaxel
- Drug: Carboplatin
- Drug: Letrozole
- Drug: Tamoxifen
Other Study ID Numbers
- MedOPP096
- 2016-002676-27
- 2016